289 related articles for article (PubMed ID: 21339222)
21. [Mycophenolate mofetil--a new therapeutic agent for chronic autoimmune diseases].
Harboe E; Gøransson L; Wildhagen K; Omdal R
Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1650-2. PubMed ID: 15976831
[TBL] [Abstract][Full Text] [Related]
22. Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?
Runkel L; Stacey J
Expert Opin Biol Ther; 2014 Apr; 14(4):491-501. PubMed ID: 24490627
[TBL] [Abstract][Full Text] [Related]
23. Why targeted therapies are necessary for systemic lupus erythematosus.
Durcan L; Petri M
Lupus; 2016 Sep; 25(10):1070-9. PubMed ID: 27497251
[TBL] [Abstract][Full Text] [Related]
24. [Progress and perspectives in the treatment of systemic lupus erythematosus].
Robak E; Sysa-Jedrzejowska A; Wozniacka A
Przegl Lek; 2005; 62(9):894-9. PubMed ID: 16541725
[TBL] [Abstract][Full Text] [Related]
25. Challenges and opportunities in SLE clinical trials.
van Vollenhoven RF
Curr Opin Rheumatol; 2013 Sep; 25(5):606-15. PubMed ID: 23917158
[TBL] [Abstract][Full Text] [Related]
26. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
Jordan NP; D'Cruz DP
Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
[TBL] [Abstract][Full Text] [Related]
27. Optimizing the use of existing therapies in lupus.
Croyle L; Morand EF
Int J Rheum Dis; 2015 Feb; 18(2):129-37. PubMed ID: 25884457
[TBL] [Abstract][Full Text] [Related]
28. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
29. Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis.
Furie R; Toder K; Zapantis E
Semin Nephrol; 2015 Sep; 35(5):509-20. PubMed ID: 26573553
[TBL] [Abstract][Full Text] [Related]
30. String of successful trials in SLE: have we cracked the code?
van Vollenhoven R
Lupus Sci Med; 2020; 7(1):e000380. PubMed ID: 32095250
[No Abstract] [Full Text] [Related]
31. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.
Bengtsson AA; Sturfelt G; Lood C; Rönnblom L; van Vollenhoven RF; Axelsson B; Sparre B; Tuvesson H; Ohman MW; Leanderson T
Arthritis Rheum; 2012 May; 64(5):1579-88. PubMed ID: 22131101
[TBL] [Abstract][Full Text] [Related]
32. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
Mosak J; Furie R
Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
[TBL] [Abstract][Full Text] [Related]
33. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.
Sthoeger Z; Sharabi A; Mozes E
J Autoimmun; 2014 Nov; 54():60-71. PubMed ID: 24958634
[TBL] [Abstract][Full Text] [Related]
34. Trials and tribulations in systemic lupus erythematosus.
Wofsky D
Bull NYU Hosp Jt Dis; 2010; 68(3):175-8. PubMed ID: 20969548
[TBL] [Abstract][Full Text] [Related]
35. Biologics in SLE: the current status.
Rajadhyaksha AG; Mehra S; Nadkar MY
J Assoc Physicians India; 2013 Apr; 61(4):262-7. PubMed ID: 24482965
[TBL] [Abstract][Full Text] [Related]
36. Update on clinical trials in systemic lupus erythematosus.
Narain S; Furie R
Curr Opin Rheumatol; 2016 Sep; 28(5):477-87. PubMed ID: 27314466
[TBL] [Abstract][Full Text] [Related]
37. A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus.
Garcia A; De Sanctis JB
Curr Pharm Des; 2016; 22(41):6306-6312. PubMed ID: 27587201
[TBL] [Abstract][Full Text] [Related]
38. Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus.
Tsang HH; Trendell-Smith NJ; Wu AK; Mok MY
Lupus; 2010 Mar; 19(3):330-3. PubMed ID: 19897521
[TBL] [Abstract][Full Text] [Related]
39. Mycophenolate mofetil as a maintenance therapy for lupus-related diffuse alveolar hemorrhage: a case report.
Al Rashidi A; Alajmi M; Hegazi MO
Lupus; 2011 Dec; 20(14):1551-3. PubMed ID: 21828160
[TBL] [Abstract][Full Text] [Related]
40. The biology behind the new therapies for SLE.
Ermann J; Bermas BL
Int J Clin Pract; 2007 Dec; 61(12):2113-9. PubMed ID: 17997810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
